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Abstract
When planning a multicentre clinical trial, it can be difficult to predict the time needed to open individual sites, and
this in turn impacts on the total number of sites needed, the budget and the time frame for a clinical trial to be
delivered successfully. This is of particular importance for funding applications with a limited time frame and
budget such as NIHR RfPB. It is more efficient and cost-effective to open the total number of sites needed at the
outset of a trial, rather than to respond later to slow site opening and recruitment. Here, we share our experience
of successfully delivering a multicentre clinical trial for a rare disease within a limited time frame and budget by
approximately doubling the number of sites initially predicted to be needed. We initially predicted 20 sites would
be needed to deliver the clinical trial, but early on in the trial, the number of sites was more than doubled to allow
successful recruitment of the target sample size within the desired time frame. Of the 48 ethically approved sites,
the median time from ethical approval of a site to opening for recruitment was 182 days (95% confidence interval
[143 to 245 days]) and ranged from 18 to 613 days. In four (9%) of these sites, part of the delay was due to
pharmacy sign off not being given when R&D had issued capacity and capability (C&C). Delays due to pharmacy
sign off varied from 10 days to over 3 months delay in two sites (94 days and 102 days). A mathematical solution to
the problem of planning a study with a short recruitment window has been given to support the planning and
costing of grants with fixed time constraints: number of sites = required sample size divided by (number of eligible
patients per site per month times recruitment rate times (the number of months accrual minus 6 months)). We expect
these results to help others who are planning multicentre clinical trials in the UK. Ethical approval from NRES
Committee South West (IRAS number 225959).
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Background
Grant applications made to the NIHR Research for Pa-
tient Benefit (RfPB) funding stream may be for a max-
imum total duration of 3 years from start to finish
(https://www.nihr.ac.uk/explore-nihr/funding-pro-
grammes/research-for-patient-benefit.htm). Allowing for
3 months study set-up, 12 months patient follow-up,
3 months data cleaning and analysis and 3 months write
up, this leaves only 15 months for site set-up and patient
recruitment. Although grants often estimate 3 months
to set up and open sites in the UK, it has been unclear
whether this is realistic due to the number of processes
required. In the UK, a central study set up includes eth-
ics and regulatory approval, study documents including
protocol, sponsor and database set up as well as forma-
tion of trial management groups. Site set up and opening
requirements include capacity and capability sign off,
pharmacy approval, staff delegation logs and site initi-
ation visits.
We successfully applied for NIHR RfPB funding for a
multicentre-randomised controlled trial in patients with
immune thrombocytopenia (ITP) [1]. As this is a rare
disease (incidence 2–3/100,000), multiple sites were
needed to recruit sufficient patient numbers to reach a
statistically valid sample size (n = 120). The grant appli-
cation included an initial estimation that 20 sites would
be needed to achieve this sample size, allowing 3 months
to set up and open these sites and 15 months to recruit
patients. Here, we demonstrate why the actual number
of sites needed was far greater than anticipated due to
the longer time frame needed to open sites, which was
highly variable and rarely within 3 months. Early on in
the trial, the number of sites was more than doubled to
allow successful recruitment of the target sample size
within the desired time frame. These results may help
others when planning the time frame and number of
sites needed for a multicentre clinical trial in the UK.
Methods
Following ethical approval, all sites were sent the trial
paperwork and capacity and capability sign off was re-
quested. In addition, pharmacy sign off and delegation
logs were sought. The site initiation visits were per-
formed remotely, enabling flexible and timely availability
from the trial team. The sponsor issued permission to
the co-ordinating trials unit to proceed with opening re-
cruitment at each site, once it was satisfied that all the
necessary study-wide actions had been undertaken prior
to the first site opening to recruitment. Site recruitment
was monitored by the overseeing trials unit. Each month,
sites provided screening reports, and all Trial Manage-
ment Groups were updated on screening and recruit-
ment numbers, with comparison to projected target
recruitment. Non-recruiting sites were contacted
personally by the chief investigator, and regular newslet-
ters were sent to sites with information about recruit-
ment rates.
The time it took from formal ethical approval of par-
ticipating sites to being fully open to recruitment has
been plotted using a Kaplan-Meier curve. The Kaplan-
Meier was used to produce the median delay with 95%
confidence intervals. We also looked at the time to the
recruitment of the first patient for all sites that were
open to recruitment. In each case, sites that did not
open before the study closed or sites which did not re-
cruit before the study closed had their data censored at
that point.
For some sites, local confirmation of C&C and the
green light from the sponsor was given prior to phar-
macy sign off and the proportion of sites delayed by this,
and the time delay this produced has also been
summarised.
A mathematical solution to the problem of planning a
study with a short recruitment window has been given
to support the planning and costing of grants with fixed
time constraints. The formula is given in the last para-
graph of the “Creation of a method for predicting re-
cruitment requirements” section.
Results
At the stage of funding application, we had estimated
that 20 sites would be needed to achieve a recruitment
of 120 patients within 15months. Initially, ethical ap-
proval was sought for 29 sites to allow recruitment con-
tingency, and we received ethical permission from these
hospitals to be participating sites on 12 June 2017. Fol-
lowing this, to boost recruitment further, we added an-
other two sites in September 2017, 10 November 2017, 6
January 2018 and the final one in June 2018.
Of the total 48 sites included in the ethics submis-
sions, 43 (90%) opened to recruitment, one of which was
closed to recruitment a month later due to a change in
PI who declined to sign the delegation log. The
remaining five sites failed to open for a variety of rea-
sons: PI change, lack of staff/trial team/pharmacy cap-
acity, restructuring and no further contact. The
additional sites were set up within the initially funded
grant and without extra cost to the funder. The cost of
the site set up was minimised by remote site initiation
visits, and within the grant, hospitals received a payment
for each patient recruited. In addition, in the UK, sites
receive some financial support to set up NIHR portfolio
studies like this.
The median time from ethical approval of a site to be-
ing open to recruitment was 182 days (95% confidence
interval [143 to 245 days]) and ranged from 18 to 613
days for one site that opened very close to the end date
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and did not recruit any patients. This is represented in
the Kaplan-Meier curve in Fig. 1a.
Part of the delay for 4 (9%) sites was due to pharmacy
sign off not having been given before the site issued
C&C. Delays due to pharmacy sign off varied from 10
days delay to over 3 months delay in two sites (94 days
and 102 days).
In addition, further paperwork was requested for seven
trusts (16%) at which the PI changed or changed their
name—one of which did not re-open to recruitment as
mentioned earlier.
Of the 43 open sites, 37 recruited to the study. The
median time from opening to the recruitment of the first
patient was 87 months [95% CI 41 to 130 days]. Only 13
of the 34 sites (35%) were able to recruit the first patient
within 30 days of opening which was expected due to
the rare nature of this disease.
Compared to the rest of the UK, the six sites based in
London were slower to open (median of 242 days) and
to recruit the first patient (median of 150 days) although
this did not reach statistical significance (p values of 0.21
and 0.07, respectively, using the log rank test). When
these two delays were combined, the resulting total time
to the recruitment of the first patient at London sites
had a median time of 427 days compared with non-
London sites of 261 days (p = 0.045) as seen in Fig. 1c.
Creation of a method for predicting recruitment
requirements
A predicted recruitment from 20 sites with a 15-month
recruitment window and an average of 3-month delay
would have produced 240 site months. With a median
of 5.2 months delay, rising to 6 months when pharmacy
sign off was included, the number of site months these
20 could produce is more likely to be 20 × (15–6) = 180
which is 75% of the original prediction.
To compensate for an unexpectedly slow set-up, add-
itional sites are usually added in a later ethics amend-
ment. Setting these sites up later means that their
available recruitment window is shortened by both a 6-
month latency in recognising the need to increase the
number of sites and a 6-month latency in time to being
open to recruitment. Therefore, to make up the 25% lost
capacity in a 15-month recruitment window (a differ-
ence between the required 240 site months and the pre-
dicted 180 site months giving a short fall of 60 site
months), a study would need to recruit an additional
50% more sites (60/(15 − 6 − 6) = 20 sites).
The most efficient method is to open additional sites
from the start of the trial. Not only does this increase
the potential recruitment window at sites, but it also re-
duces the trial team resource needed to submit add-
itional ethical amendments and later site initiation visits.
A study that needed 20 sites for 12 months would recruit
27 sites for a 15-month accrual period with the know-
ledge that some sites would be much slower than others
to open for recruiting with an average latency of 6
months. If the accrual period is limited to 12months,





Fig. 1 a Proportion of sites not open. b Proportion of open sites
with no participants. c Proportion of sites with ethics but
no participants
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The formula for the number of sites required that
could be used to plan a future trial becomes: required
sample size divided by (number of eligible patients per
site per month times recruitment rate times (the number
of months accrual minus 6 months)).
Conclusions
Large multisite clinical trials of a medicinal product can
pose particular challenges when costing the grant appli-
cation, owing to the significant variation in the length of
time it takes sites to open to recruitment. A trial with a
short recruitment window will suffer the most from de-
lays in this process. For example, to complete a trial with
a 12-month recruitment window to time and target,
double the number of sites may be needed. Funders may
need to be aware of the increased costs associated with
the burden of obtaining additional sites or might con-
sider allowing extensions for trials of rare diseases. In
addition, close monitoring of site opening and recruit-
ment are also essential, with proactive measures taken if
the trial is behind target.
Acknowledgements
We are particularly grateful to the UK ITP forum and the ITP support
association who have supported this research and are also very grateful to
the participating sites and patients.
Authors’ contributions
RG is the trial statistician and wrote the first draft of the manuscript. CB is
the lead investigator for this research. JP and IT were responsible for the trial
management. PF was responsible for the data management. KW was the
trial sponsor representative. All authors reviewed and critically appraised the
manuscript. The authors read and approved the final manuscript.
Funding
NIHR Programme Grant: PB-PG-0815-2016. The NIHR did not contribute to
this letter.
Availability of data and materials
Not applicable
Ethics approval and consent to participate





The authors have no competing interests to declare.
Author details
1School of Translational Health Sciences, University of Bristol, Bristol, UK.
2University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
3Cardiff University Centre for Trials Research, Cardiff, UK.
Received: 19 May 2020 Accepted: 10 October 2020
Reference
1. Pell J, Greenwood R, Ingram J, Wale K, Thomas I, Kandiyali R, Mumford A,
Dick A, Bagot C, Cooper N, Hill Q, Bradbury CA. Trial protocol: a multicentre
randomised trial of first-line treatment pathways for newly diagnosed
immune thrombocytopenia: standard steroid treatment versus combined
steroid and mycophenolate. The FLIGHT trial. BMJ Open. 2018;8(10):e024427.
https://doi.org/10.1136/bmjopen-2018-024427 Published online 2018 Oct
18.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Greenwood et al. Trials          (2020) 21:873 Page 4 of 4
